

SNIPR Biome extends collaboration with Novo Nordisk to continue advancing microbial gene therapy approach

Copenhagen, August 8, 2023: SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy today, announces the continuation of its research collaboration with Novo Nordisk, with the aim of establishing preclinical proof of concept for a novel target within cardiometabolic disease. This funded research agreement further validates SNIPR’s microbial gene therapy technologies and builds upon the research collaboration that the two companies began in June 2021.

SNIPR Biome’s microbial gene therapy platform enables the production of therapeutic proteins and peptides in the gut of patients. The technology has broad applicability in a variety of indications with high unmet medical need.

Dr Christian Grøndahl, CEO and co-founder of SNIPR Biome, commented: *“We are excited by the progress we have made during the past two years, and we welcome the opportunity to continue our productive partnership with Novo Nordisk within the cardiometabolic disease space. Our gene therapy technology has the potential to develop new treatments, bringing about significant advancements in medicine and for patients.”*

ENDS

About SNIPR BIOME

SNIPR Biome is a clinical stage company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy. The company’s pipeline is built on two key technology platforms. One is focused on harnessing the potential of engineered bacteria to deliver therapeutic payloads (e.g., antibodies, peptides, hormones, enzymatic pathways) to the human gut, where the therapeutic effect is exerted. The second is focused on selective bacterial killing, for which SNIPR001 recently demonstrated clinical proof of principle through the targeted eradication of antibiotic resistant *E. coli* in the gut. The groundbreaking research and preclinical work supporting SNIPR001 have been published in Nature Biotechnology.

SNIPR Biome is proud to partner with CARB-X (on SNIPR001), Novo Nordisk (in the engineered bacterial space), and MD Anderson Cancer Center. Based in Copenhagen, Denmark, SNIPR Biome is backed by a strong syndicate of investors including Lundbeck Foundation Biocapital, EQT, North East Family Office and Wellington Partners. For more information, visit www.sniprbiome.com and follow us on LinkedIn and Twitter.

Contacts

SNIPR Biome

Dr Christian Grøndahl, Co-founder and CEO

E-mail: cg@sniprbiome.com

Mobile: +45 20202747

www.sniprbiome.com

Please follow us on LinkedIn & Twitter: @sniprbiome

Consilium Strategic Communications

Tracy Cheung, Chris Welsh, Davide Salvi

Tel: +44 (0) 203 709 5700

SNIPR@consilium-comms.com